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Context: In recent decades, natural products have undisputedly played a leading role
in the development of novel medicines. Yet, trends in the pharmaceutical industry at the
level of research investments indicate that natural product research is neither prioritized
nor perceived as fruitful in drug discovery programmes as compared with incremental
structural modifications and large volume HTS screening of synthetics.
Aim: We seek to understand this phenomenon through insights from highly experienced
natural product experts in industry and academia.
Method: We conducted a survey including a series of qualitative and quantitative
questions related to current insights and prospective developments in natural product
drug development. The survey was completed by a cross-section of 52 respondents in
industry and academia.
Results: One recurrent theme is the dissonance between the perceived high potential
of NP as drug leads among individuals and the survey participants’ assessment of the
overall industry and/or company level strategies and their success. The study’s industry
and academic respondents did not perceive current discovery efforts as more effective as
compared with previous decades, yet industry contacts perceived higher hit rates in HTS
efforts as compared with academic respondents. Surprisingly, many industry contacts
were highly critical to prevalent company and industry-wide drug discovery strategies
indicating a high level of dissatisfaction within the industry.
Conclusions: These findings support the notion that there is an increasing gap in
perception between the effectiveness of well established, commercially widespread
drug discovery strategies between those working in industry and academic experts.
This research seeks to shed light on this gap and aid in furthering natural product
discovery endeavors through an analysis of current bottlenecks in industry drug discovery
programmes.
Keywords: natural products, drug discovery, academia-industry links, Big Pharma, HTS, strategy
Abbreviations: GBIF, Global Biodiversity Information Facility; HTS, high throughput screening; NP, natural products; SAR,
structure-activity relationships; SD, standard deviation; SME, small medium enterprise; VS, virtual screening.
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INTRODUCTION
Historically, natural products (NP) development has been a
field of immense interest to medical, commercial, and scientific
communities worldwide. As isolation and purification techniques
advanced, NP increasingly became prime candidates for drug
leads and drug discovery efforts (Cragg et al., 1997; Heinrich
and Gibbons, 2001; Heinrich, 2013). Their diversity characterizes
them as a virtually limitless source of novel lead compounds.
Yet in the last decade, the majority of multinational
pharmaceutical companies have reduced NP Research and
Development (R&D) expenditures (David et al., 2014). Many
of the largest pharmaceutical companies are aggressively
downsizing internal scientific research teams and reducing
cost/risk by focusing instead on acquisitions of SMEs, which do
the bulk of discovery “legwork” for a particular compound as it
gets pushed through the pipeline.
What are elements behind this? What are the common
drivers and barriers in natural product development? How
can efforts to understand such drivers and barriers (Amirkia
and Heinrich, 2014) enhance our ability to further leverage
the potential of NPs? If NPs have historically been such
an important source of new medicines, what insights can
we gain into the NP drug development process of academic
stakeholders as compared with the widely recognized slowdown
of industry efforts? What are the differences in insights between
successes of NP drug discovery today among in industry and
academia? Through this research, the authors seek to gain
insight into these questions by directly soliciting the views of an
unprecedentedly large panel of pharmaceutical industry experts
who currently serve in senior positions in academic/commercial
organizations. To be best of our knowledge, it is the first
published survey of stakeholders in the NP drug discovery
sector.
BACKGORUND: CURRENT CONTEXT OF
DRIVERS AND BARRIERS IN NATURAL
PRODUCT DEVELOPMENT
A brief but representative selection of NP development and
drug discovery-related opinion, review, and primary literature
published over the last two decades shows a range of varied,
often contrasting viewpoints on the potential of NPs as drug
leads/candidates (Table 1). The majority of published literature
hails the potential of NPs as sources of structurally novel, highly
diverse compounds and cites examples of how NPs comprise a
high proportion of successfully marketed new medicines over
the last 20 years. The voice of optimism is loud and clear
and has generally overshadowed a number of critical voices
which have pointed out major challenges in NP development
such as extraction and supply issues (McChesney et al., 2007).
Additionally, many have added fuel to this debate through
focusing on academia-industry partnership initiatives, inter-
disciplinary approaches such as virtual screening methods and
genomics efforts; one example being Shen’s paper in 2003 which
outlined three main advantages of virtual screening of natural
products. He argued that virtual screening provides: higher hit
rates as compared with typical HTS assays thus saving time/cost.
Additionally he considers it to be more effective in investigating
the about 90% of the “natural diversity” which so far have not
been explored (defined as species which have yet to be studied
systematically in research settings), and increased prediction of
ADME/Tox and other drug like properties which may show
promise in diminishing missed/failed hits (Shen et al., 2003;
Bohlin et al., 2010).
One limitation of many if not all of these studies is that in
essence they are based either on an assessment of new drug
(leads) or are basically opinion papers. The authors normally
had not engaged with a substantial number of stakeholders from
within the pharmaceutical industry; most importantly those who
currently work in the industry. Understandably so, not only is
it challenging to track down a meaningful number of industry
decision makers with experience in NP drug development but
perhaps the larger challenge is eliciting their views (often which
are critical of their superiors) pertaining to their company’s
strategy and/or industry trends. The authors believe that this
internal lens, through angles such as commercial operations,
strategic planning, research and development, and senior
management is essential in gaining a clearer understanding of
the role of NP discovery and development as it contributes to
drug development in general, as well as the gaps, and potential
advances in academia-industry partnerships to advance drug
discovery efforts.
METHODS: ENGAGING INDUSTRY
CONTACTS
A panel of industry and academic contacts (most of which
are personal contacts of one or both of the authors) were
personally invited to participate and submit insights to a natural
products development survey which was hosted online (Google
Forms—http://forms.google.com). A snowballing strategy was
used to increase the number of contacts. Industry contacts
represented many of the major multinational pharmaceutical
companies such as Merck, Novartis, GSK, Pfizer, AZ, and
Bayer. Seniority of each respondent varied with respect
to his or her organization. Titles of respondents included:
Chief Scientific Officer (CSO), President, Vice President (VP),
Group Leader, Senior Analytical Chemist, and Senior Principal
Scientist (Appendix 1 in Supplementary Material) among
others.
Academic contacts originated from eight different countries
including Brazil, Oman, New Zealand, UK, and USA. The
majority of academic respondents were full-time academics,
five of which also hold senior roles in pharmaceutical-
company related organizations (consultancy, clinical research,
and/or pharmaceutical entities). The panel is clearly limited
in its geographical coverage of smaller pharmaceutical markets
such as Asia, Japan, and Latin America; markets which
represented approximately 11, 9, and 5% of 2014 total
worldwide pharmaceutical sales, respectively (IMSHealth, 2014).
Nevertheless, barring the extreme of labeling the panel as strictly
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TABLE 1 | Selection of representative publications on the outlook of NPs as drug leads in modern drug discovery programs and their overall levels of
optimism.
Title Author and year of
publication
General outlook/Tone*
Recent natural products based drug development: a pharmaceutical industry perspective Shu, 1998 Optimistic
Natural product drug discovery in the next millennium Cragg and Newman, 2001 Optimistic
Natural products in the process of finding new drug candidates Vuorelaa et al., 2004 Optimistic
The role of natural product chemistry in drug discovery Butler, 2004 Neutral
The renaissance of natural products as drug candidates Paterson and Anderson, 2005 Optimistic
Drug discovery from medicinal plants Balunas and Kinghorn, 2005 Optimistic
The evolving role of natural products in drug discovery Koehn and Carter, 2005 Optimistic
Drug discovery from natural products Gullo et al., 2006 Optimistic
Drug discovery from natural sources Chin et al., 2006 Optimistic
Plant natural products: back to the future or into extinction? McChesney et al., 2007 Pessimistic
Challenges and opportunities in drug discovery from plants Jachak and Saklani, 2007 Optimistic
A review of high throughput technology for the screening of natural products Mishra et al., 2008 Neutral
New aspects of natural products in drug discovery Lam, 2007 Neutral
The value of natural products to future pharmaceutical discovery Baker et al., 2007 Neutral/Pessimistic
Molecular understanding and modern application of traditional medicines: triumphs and trials Corson and Crews, 2007 Neutral/Optimistic
Natural products in drug discovery Harvey, 2008 Optimistic
Natural products as a robust source of new drugs and drug leads: past successes and present day issues Rishton, 2008 Neutral
Drug discovery and natural products: end of an era or an endless frontier? Li and Vederas, 2009 Neutral
Modern natural products drug discovery and its relevance to biodiversity conservation Kingston, 2010 Optimistic
The impact of the united nations convention on biological diversity on natural products research Cragg et al., 2012 Neutral
The pharmaceutical industry and natural products: historical status and new trends David et al., 2014 Neutral
The re-emergence of natural products for drug discovery in the genomics era Harvey et al., 2015 Optimistic
*The general outlook the potential contribution of natural products in modern drug discovery efforts is summarized as pessimistic, neutral, and/or positive. Clearly the overall optimism
in published assessment contrasts with the current trends in R&D activities in the pharmaceutical industry.
representative of “the industry,” the authors feel that the panel of
contacts is generally representative of trends of interest within the
industry.
There were four primary goals which were considered in
designing the questionnaire:
(1) To understand perceived drivers and barriers in NP drug
discovery efforts.
(2) To understand what respondents identify as “current
preferred strategies” for discovering new medicines in
industry today.
(3) As HTS stands as a prevalent tool in in drug discovery
today we wanted to elicit perceptions of the efficacy of NPs
as compared with other classes of compounds in screens.
(4) To understand the respondent’s general outlook on future
drug discovery as a whole. This approach would allow the
authors to better understand the perceived effectiveness
of past, present, and future NP drug discovery efforts
and more importantly compare any potential similarities
and differences in insights between academic and industry
respondents.
The survey consisted of a series of six quantitative and qualitative
close-ended questions followed by 10 profile and background
related questions. Close-ended questions with several choices had
an “other” box for the respondent to fill in his/her response which
allows for valuable straightforward feedback from respondents
and helps overcome the limitations of extensive statistical
analyses based of a small sample size. Multiple choice selections
were displayed in randomized order for each survey so as to
control for position bias in responses. Close-ended questions
were comprised of:
(1) In your opinion, what are the top 2 current preferred
strategies for drug discovery?
(2) Based on your experience or on your assessment,
approximately how many agents based on natural products
and alkaloids researched in commercial R&D facilities make
it to market as pharmaceutical products?
(3) From your experience, what have been the major drivers to
natural product development in industry?
(4) From your experience, what have been the major barriers to
natural product development in industry?
(5) Drug Discovery is a history of triumphs and failures.
Compared to last decades how successful is the industry
today in discovering new medicines?
(6) What is your outlook on the future viability (rate at which
pharmaceuticals are developed and launched to market)
of natural products, serving either as final pharmaceutical
products or as leads to the development of the final
pharmaceutical products?
The six close-ended questions each had an open field for
participants to provide additional thoughts. Total completions of
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the survey ended at 52 responses after 14 weeks spanning from
January to May 2015.
RESULTS AND DISCUSSION
Overview of Findings
One major, consistent theme across respondents was the
dissonance between what survey participants in industry
perceived as the potential of NP as drug leads and overall
industry and/or company level strategies. Large scale, structural
modification processes (i.e., HTS) have become Big Pharma’s go-
to-strategy for honing in on successful leads. HTS typically avoids
the need to continuously source and verify new NP material,
which matches the highest citied barrier from industry contacts
in our survey (i.e., a secure supply). Additionally, large HTS
screening programmes are argued by many (Macarron et al.,
2011) to be more cost-effective in the long run which is also in
line with the third largest barrier cited by our industry contacts
(i.e., cost/funding/budget). Sample sizes of respondent groups are
not sufficiently large enough to perform useful statistical analysis
yet general results are summarized below (Table 2).
Two other major themes emerged from participants writing
insights in the open space provided after each close-ended
question and are illustrated with a selection of verbatim
statements pertinent to each theme.
Ineffectiveness of Current HTS Drug Discovery
Programmes
Industry efforts which boast large libraries and cutting edge
screening technologies have gained momentum which in turn
has overshadowed smaller, more unique and fruitful discovery
efforts.
• “The industry focus on numbers (quantity vs. quality) has
counted against natural products discovery—and the belief that
supply of material on a suitable scale might be difficult (which
may be a misconception).”
• “Industry is driven by numbers and processes; HTS, you could
include fragment screening in this too—or even billions of
compounds on encoded libraries (as we have at [X] company).
I am part of a group who strongly advocate the huge impact of
proper attention to physical properties and efficiency as existing
leads are optimized (sadly mostly derived from the numbers
generated above). HTS yet is the adopted strategy; in my opinion
is probably isn’t the most preferred!”
• “These approaches [High throughput screening (HTS),
Combinatorial Chemistry] are favored by many pharmaceutical
companies, even though they have not been notably successful.”
• “HTS depends on large libraries, most of which have been
so thoroughly studied that their utility going forward must be
considered modest.”
• “My understanding is that physicochemical modifications of
existing leads represents the vast majority of drug discovery, and
there are few places which are supporting anything beyond HTS
or medicinal chemistry cycles.”
• “Based on our internal track record, the outcome of HTS or
VS is heavily dependent on the quality (control) of the actives
and their ligand efficiency and the access to orthogonal assays to
confirm the activity. These methods also complement each other
and can be supported by additional methods, e.g., fragment-
based. They are also generally easier to strip to the ‘core’ and
obtain initial SAR. With natural products, you need to be lucky
with the minor metabolites yielding some useful SAR.
Nevertheless, our experience at X University. . . screening
endogenous X species was successfully generating leads that were
NOT pursued as chemists perceived the SAR work to have low
feasibility.”
• “In industry, modification of existing structures whether already
in-house identified compounds or to bypass other structures
with patent protection is much more common. This allows
for the creation of “me too” therapeutic agents. Bioprospecting
is much more common in academia, but natural product
identification seems to be decreasing on the whole. Whether this
is purely due to funding issues or a broader shift in the field is
not certain. Similarly, virtual/computation approaches are used
in refining structure in industry but are essentially never used to
de novo identify a drug.
“Many academic labs have used such strategies as well, but with
few successes. HTS is still fairly common place in industry and is
gaining greater traction in academic settings with more and more
universities creating screening facilities. Serendipity is certainly
an important part of drug discovery, especially in areas such as
neurology, but no one would bet on winning the lottery to fund
their lab.”
• “HTS has been an abject failure in terms of discovery, due
in most cases to not thinking about transfer across membrane
issues when trying to go from a hit to an active in cells/animals.
If one uses phenotypic screening (a dirty term amongst screeners
in Pharma!), then if you see a valid effect, you will be well ahead of
any HTS assay in vitro.”
• “In Pharma, HTS is the buzzword. I know of screens where
over 1 million synthetic compounds have produced nothing,
many times. Natural products in phenotypic screens are between
10,000 and 100,000 depending upon what is known about
potential mechanisms etc.”
The Second Key Theme That Emerged Centers
around the Lack of Support/interest in Organization
for NP Drug Development Efforts
Industry strategy over the last few decades has taken its form
against a NP-centric strategy and is unlikely to change.
• “Don’t fit company strategy.”
• “Executive management fiat. Senior and executive scientific
management at most Big Pharma wrote off natural products in
the late ‘80s and early ‘90s with the advent of HTS, believing that
HTS would have all of the answers.”
• “Hostility; No support.”
• “Lack of will to study them.”
• “Natural product discovery tends to require a group to
champion the approach. In my experience med chemists
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TABLE 2 | Results of the survey including selected close ended and profile questions.
Industry respondents (n = 33) Academic respondents (n = 19)
Average age 53 48
Average years of experience in the pharmaceutical
industry
25 10
Male/Female 82% Male, 18% Female 89% Male, 11% Female
Drug Discovery is a history of triumphs and failures.
Compared to last decades how successful is the
industry today in discovering new medicines?
3.9* (SD:1.22) 4.3* (SD:1.37)
In your opinion, what are the top current preferred
strategies for drug discovery?
1. High throughput screening (HTS)—31%
2. Physiochemical—modifications to existing
leads—25%
3. Virtual/Computational prospecting/modeling—19%
1. High throughput screening (HTS)—34%
2. Physiochemical—modifications to existing
leads—24%
3. Virtual/Computational prospecting/modeling—18%
Top Drivers to natural product development in
industry1
1. Structural Novelty and Bioactivity—47%
2. Efficacy and/or chemical viability (solubility, stability,
toxicity, etc.)—18%
3. Supply—11%
1. Structural Novelty and Bioactivity—42%
2. Efficacy and/or chemical viability (solubility, stability,
toxicity, etc.)—24%
3. Cost/Funding/Budget—15%
Top Barriers to natural product development in
industry1
1. Supply—26%
2. Structural Complexity—20%
3. Cost/Funding/Budget—19%
1. Cost/Funding/Budget—25%
2. Structural Complexity—23%
3. Supply—25%
What is your outlook on the future viability (rate at
which pharmaceuticals are developed and launched
to market) of natural products, serving either as final
pharmaceutical products or as leads to the
development of the final pharmaceutical products?2
Optimistic—52%
Unsure/“Hard to say”—21%
Pessimistic—27%
Optimistic—63%
Unsure/“Hard to say”—26%
Pessimistic—11%
*Respondents were asked to rank the success of natural product based drug discovery efforts from 1 = Full of Triumph to 7 = Full of Failure. The values given are the averages from all
responses.
don’t switch between synthetic chemistry and natural product
chemistry. The latter requires an infrastructure and senior
champions who believe in the potential of the approach. The
novelty of the structures that result often go beyond anything
that a med chemist might consider synthesizing as such this can
take you to places you wouldn’t have got to by any other route.”
• “Screening of synthetic chemicals in massive libraries is cheap
and most often results in hits that can be optimized as
leads effective against sign targets. This process discounts any
deep understanding of the biological processes involved in a
disease state, other than the role played by an individual
target biomolecule (kinases, etc.). And, the chemistry involved
in elaborating these often simple structures is easy and high
throughput—so from the chemists standpoint—why knock
yourself out with NP modifications which are often more
difficult? Regrettably in industry little credit is given for the extra
effort and overall productivity will appear low.”
• “The major driver to natural product development in industry
is to eliminate it, which is what most of the large pharma
companies have in fact done.”
• “From my perspective, today, natural products make only sense
as starting materials for further optimization. I am convinced
that we will see less and less original natural products that make
1Respondents could select or list more than one response. All responses were
added together and a “response rate” was calculated by taking the percentage of
a particular response as a total of all responses.
2Respondents selected one response. All responses were added together and a
“response rate” was calculated by taking the percentage of a particular response
as a total of all responses.
it to the market in human pharma (animal health may be a
different story). Also TCM et al. may be a different story.”
• “NPs are currently not the “flavor of the month or decade” but
now days, chemists are looking for structural leads that may well
have activity, due to the failure of combi-chem as a discovery
tool.”
It is interesting to note that such an open question in fact only
elucidated two key reasons why natural products are poorly
represented in such drug discovery processes. Open questions are
often used to elicit a wider set of views (Heinrich et al., 2009)
and here a clear focus on two concerns emerged indicating a very
strong consensus on that these are seen as the key issues.
Perceived Viability of Natural Products
among Current Drug Discovery
Programmes
Gaining insights into perceptions of the drivers and barriers of
NP drug discovery is a helpful yet limited step in providing
insights into the drug development process. This data does
not convincingly indicate the “effectiveness” of NPs in drug
discovery as compared to other commonly researched classes
of compounds. Thus, we asked respondents to provide an
approximate ratio of “success rates” for several classes of
compounds in the following way: Based on your experience or on
your assessment, approximately how many synthetic [or Biologics,
Natural Products, Alkaloids] agents researched in commercial
R&D facilities make it to market as pharmaceutical products? This
resulted in four sets of answers relevant for each of these groups.
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TABLE 3 | Respondent’s estimates of how many agents researched
commercial R&D facilities make it to market as pharmaceutical products
(defined as the “hit rate”).
Compound
Class
Industry respondents
(n = 33) (Logarithmic
value)
Academia respondents
(n = 19) (Logarithmic
value)
All natural
products*
4.03 (1 in 10,723) 4.53 (1 in 33,598)
Alkaloids 4.27 (1 in 18,738) 4.53 (1 in 33,598)
Synthetic
compounds
4.97 (1 in 93,260) 5.26 (1 in 183,298)
Biologics 3.67 (1 in 4642) 4.11 (1 in 12,743)
Overall
average
4.24 (1 in 17,179) 4.61 (1 in 40,504)
Respondents selected from a range of six responses beginning at “1 in 100” and ending
at “1 in 1,000,000+.” Averages were calculated by assigning a value between 2 and 7
to each response and extrapolating through a logarithmic calculation (e.g., 102 = 100,
106 = 1,000,000). *All natural products includes alkaloids.
Interestingly, all perceived “hit rates” for industry respondents
are higher than those academic respondents reported (Table 3).
Industry respondent “hit rates” were higher at a rate ranging
between 1.8 and 3.1-times. This may reaffirm our other
finding that in general, senior stakeholders in industry
typically do support NP-centric discovery strategies, and
hence the more perceived frequent “hits.” Conversely, this
indicates that screening programmes related to academic
efforts, particularly with respect to HTS, are not perceived
as being as useful more widespread industrial efforts. Does
this mean that industry is more “productive” than academia
in screening for natural products? Not necessarily, as this
question does not attempt to equalize all screening methods
but rather gain a general indication of respondent’s perceptions
toward screening efforts. Additionally, it is also surprising to
note that there is a larger gap between “hit rates” reported
between NPs and synthetics for industry vs. academic
respondents; 8-times vs. 5-times, respectively. This also
indicates a reaffirmation to our previous observation that
many working in industry—regardless of their role and their
level of dissatisfaction with the strategic direction of their
organization, still perceive strong relative potential in NP
drug development as compared with currently prevalent
synthetic-centric strategies.
Our goal in asking this question is two-fold; to gain a general
indicator of perceived “success/hit rates” of NPs against other
compound classes as well as compare the perception of “success
rates” against previous claims published over the years by
industry observers (Shen et al., 2003). There are two limitations
to this question. The first is that each respondent may define
“researched” in a completely differing way. To one respondent
a compound is not “researched” until it perhaps enters a HTS
program, while to another, a compound merely existing in a
company compound library may count as being “researched.”
The second is the definition of the compound class (for example:
Where does a NP which has been structurally modified fit?). Of
course, there are numerous variables in any screen (compound
library itself, target/ligands, parameters for defining a successful
“hit,” purpose of screen, etc. . . ) that make a particular screen
entirely unique and incomparable to another.
Potential Steps Forward
Since 35 of the 52 respondents (35 of all 105 individual answers
to this open question) listed HTS as a “top preferred current
strategy,” it is logical that this should be a focus of our analysis.
Many publications have cited barriers to NP drug development.
In 2004 Jean-Yves Ortholand, who at the time worked at
Merck in France, listed six major drawbacks in programmes
screening natural products: expense, time, novelty, tractability,
scale-up, and intellectual property (Ortholand and Ganesan,
2004). In looking to our industry feedback, each of Ortholand’s
“drawbacks” are corroborated to some extent with a particular
focus on supply and cost/funding. It is noteworthy that these two
highly cited barriers do not directly involve the actual screen itself
but rather affect the feasibility of pre/post-screen efforts. The
most frequently cited barriers seem to be those which prevent
a screen from happening in the first place (i.e., budget/cost or
company strategy) or from moving from early stage screening
to pre-clinical development (i.e., supply, scale-up). Therefore,
besides proposing the obvious that costs should be reduced
and/or funding increased for NP drug discovery efforts, are
there potential cost-sensitive resolutions to the supply/scale-up
barrier?
Our previous research (Amirkia andHeinrich, 2014) looked at
the problems of supply in the context of source species abundance
data of pharmaceutical alkaloids. We showed that source species
of pharmaceutical alkaloids are on average 4.3 times more
“abundant” [as defined by the Global Biodiversity Information
Facility (GBIF) species abundance dataset] than a randomly
picked non-pharmaceutical alkaloid. Alkaloid containing species
yielding medicines are thus much more widely distributed
than species which yield alkaloids not used pharmaceutically.
This suggests that such a dataset is sufficiently significant for
modeling supply constraints which are so often cited in NP
related literature. Although this initial analysis was performed on
alkaloids, it can be applied to any class of NPs.
Taken together our data show that such an analysis can be
augmented with other metrics such as number of countries
which host species naturally occur in or density of source species
abundance (Amirkia and Heinrich, 2014). Here key questions
include:
• Is the source species widely spread across one region or densely
found in one small area?
• How many countries does the species naturally grow in?
• How are occurrences of the species in the dataset distributed
across time? Were instances discovered and recorded decades
ago or have records been relatively consistent?
Instead a systematic assessment of a species’ abundance can play a
constructive pre-screening or filtration role in NP drug discovery
programmes which directly addresses one of the key concerns
of the stakeholders who contributed to this study. Costs for
such analyses are minimal compared to R&D budgets common
to pharmaceutical companies today. Additionally such analyses
need not necessarily be exclusively seen as applicable to screening
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programmes for candidates or leads but may prove to be of
value in other NP-related endeavors. For example, companies
which are heavily invested or interested in TCM, Ayurveda,
and other traditional medicine centric portfolios may use this
approach to optimize procurement or investment processes.
Compounds which originate from source species which are
becoming increasingly abundant may hold more promise long-
term sustainability in production and marketability.
CONCLUSIONS
NPs are seen as important sources of new medicines by industry
stakeholders, yet, the industry is spending fewer and fewer
resources on their discovery and development. In the last
decade numerous voices have highlighted this concern with the
vast majority of these originating from academic and industry
observers (Niedergassel and Leker, 2009; Tralau-Stewart et al.,
2009; Khanna, 2012). Two thirds of panel responses cited HTS
as the preferred strategy for drug discovery in industry today
and NPs are seen as yielding higher “hit rates,” thus industry
attention must not turn away from NPs if the industry seeks
innovation. This gap must be explored if we are to move natural
product drug discovery forward and virtual non-ligand machine
learning, at least for alkaloids, can serve as a starting point to
guide multidisciplinary drug discovery efforts.
While this study has some limitations both in terms of the
overall size of the sample and the (self-) selection of participants,
the voices from within clearly highlight some key concerns,
which can be overcome by implementing a modified strategy
in NP-driven drug development. Minimizing one of the most
commonly cited barriers (i.e., supply) by seeking to quantifying
it and developing strategies for incorporating solutions at an
early stage of screening programs is one approach which has
demonstrated promise for alkaloids and can be applied to other
NP drug discovery efforts. The work also strengthens the case
that “weeds” are an important source of drugs (Stepp, 2004),
but offers a quantifiable parameter to assess such “weediness.”
Continuing along the current path of large “numbers-driven”
screens which boast millions of compounds not only has irritated
many, at all levels, in the industry but more importantly
stifled the growth and development of the single most
productive source of potential leads for new medicines to date;
nature.
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